news roundup

Take Our Survey!

Applied Clinical Trials and SCORR want to know more about your innovations in clinical trial design. Please take this brief, 25-question survey to give us insight on your design process, resources needed to make changes, benchmarks used to measure performance of changes, and the impact new clinical trial designs have had on your work.

ClinicalStudyDataRequest.com Announces Partnerships with Global Academic Research Funders

ClinicalStudyDataRequest.com announced new collaborations with four major non-profit partners: The Bill & Melinda Gates Foundation, Cancer Research UK, Medical Research Council, and Wellcome Trust. These new consortium partners will expand researchers' access to patient-level clinical trial data.

Novartis Launches FocalView app

Novartis announced the launch of its FocalView app, an ophthalmic digital research platform created with ResearchKit. This app is designed to collect data directly from patients in order to track disease protection and allow them to particpiate in ophthalmology clinical trials from home.

Clinical Trials Xpress, Named as a PAREXEL Strategic Site Alliance Network Member

Clinical Trials Xpress (CTX), an initiative of the University of Texas System, has been named by PAREXEL as a member of its Global Site Alliance Network. Within this network, CTX will work side-by-side with PAREXEL to promote more clinical development of drug therapies through research.

Articles

Barriers and Solutions to Smart Clinical Program Designs

How the Clinical Development Design (CDD) Framework can offer repeatable, reusable clinical designs based on "enabling information."

The Impetus for Natural History Studies in Rare Disease R&D

The use of natural history (NH) studies early in clinical research can help facilitate development programs for orphan drugs.

Oncology

Oncology Therapy-Focused RACT Emerges

Newest revelations suggest Risk Assessment Categorization Tools are now becoming therapeutic area-specific, as an oncology-based risk library is now surfacing.

Ask the editor

Lisa Henderson
Editor in Chief
Lisa.Henderson@ubm.com